Using data from over 16,000 patients, half of whom received semaglutide at a dose of 2.4 mg weekly, the authors reported an improvement in renal outcomes even in patients without diabetes
According to Woo-Jin Song and colleagues: "Most, if not all effects of GLP-1 and E4 in beta cells appear to require intracellular activation of the adenosine-3-5-cyclic monophosphate (cAMP)- protein kinase A (PKA) signaling pathway by the G-protein coupled receptor of GLP-1, which is highly expressed on pancreatic beta cells
A: Yes, daily supplementation is safe within the recommended range, typically 500 to 3000 milligrams depending on your goals
Int J Obes (2012) 36:84354
The challenge is to capture these catabolic and hepatometabolic benefits without producing unacceptable hyperglycemia
Therefore, management of both is crucial for treatment and improved outcomes. GLP-1RAs and, more recently, twin-cretins (GLP+GIP) are often used in patients with diabetes and with or without obesity